Insulin– tag –
-
Sana Biotechnology to Initiate Hypoimmune Cell Therapy and In Vivo CAR T Trials This Year, with Data Expected Within 12 Months
TradingView USA Overview Sana Biotechnology is set to commence clinical trials for two key platforms this year: a hypoimmune cell therapy targeting Type 1 diabetes and an in vivo CAR T platform for oncology and autoimmune diseases. Initi... -
Century Therapeutics to Present iPSC-Derived CNTY-813 (Featuring Allo-Evasion™ 5.0) for Type 1 Diabetes at ADA 86th Scientific Sessions
Benzinga USA Overview Century Therapeutics is scheduled to deliver an oral presentation on its innovative iPSC-derived islet cell replacement therapy, CNTY-813, for Type 1 diabetes at the American Diabetes Association (ADA) 86th Scientif... -
Molecularly Recognized Polymeric Soft Materials: Glucose-Responsive Hydrogels Enable Closed-Loop Insulin Delivery
Taylor & Francis Online International Overview This review reports advances in molecularly recognized polymeric soft materials, particularly glucose-responsive hydrogel systems. These hydrogels are fabricated into microneedle patches for... -
Abbott Secures CE Mark for World’s First Dual Glucose-Ketone Sensor, Revolutionizing DKA Management
MedTech Dive USA Overview Abbott has received European CE Mark approval for its Libre Duo and Libre Duo 10 Day systems, the world's first dual-analyte sensors capable of continuously measuring both glucose and ketones. This technology ai... -
Sana Biotechnology Reports 14-Month Positive Clinical Results for Immunosuppression-Free iPSC-Derived Islet Cell Transplant in Type 1 Diabetes
Simply Wall St (via Nasdaq:SANA) USA Overview Sana Biotechnology announced continued positive clinical results from its study of iPSC-derived islet cell transplantation (UP421) for Type 1 diabetes, spanning 14 months without immunosuppre... -
FDA Clears Dexcom Stelo: First Over-the-Counter Continuous Glucose Monitor to Transform Non-Insulin-Dependent Diabetes Management
U.S. Food and Drug Administration (FDA) News Release USA Overview The U.S. FDA has cleared the Dexcom Stelo Glucose Biosensor System, the first over-the-counter (OTC) continuous glucose monitor (CGM) for individuals aged 18 and older not... -
Vertex’s Zimislecel Cell Therapy Achieves Insulin Independence in 10 of 12 Type 1 Diabetes Patients
Breakthrough T1D Australia Overview Vertex Pharmaceuticals announced highly promising results from its FORWARD-101 trial of Zimislecel (formerly VX-880), an iPSC-derived cell therapy for Type 1 Diabetes (T1D). Ten of 12 participants achi... -
Cell-Easy Launches Large-Scale iPSC-Derived Beta Cell Program to Address Manufacturing Bottlenecks for Diabetes Therapy
BioInformant USA Overview Cell-Easy has initiated a new program focused on scaling up the manufacturing of iPSC-derived beta cells, addressing a critical bottleneck for diabetes therapies. This initiative aims to establish a stable, high... -
Genprex Collaborators Report Positive Preclinical Data for Diabetes Gene Therapy at ASGCT 2026, Showing Alpha-to-Beta Cell Reprogramming
PR Newswire USA Overview Genprex's collaborators presented positive preclinical data at ASGCT 2026 for GPX-002, a gene therapy candidate for Type 2 Diabetes (T2D). The therapy, which delivers Pdx1/MafA genes to the pancreas via an AAV ve...
